Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study
Autor: | Alhassane Diallo, Boubacar Bah, Fulgence N’Zabintawali, Boubacar Diallo, Lansana Mady Camara, Oumou Sow, Mamadou Hassimiou Diallo, Lucrèce Ahouéfa Nadège Kounoudji, Miguel Carlos-Bolumbu |
---|---|
Přispěvatelé: | Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Department of Epidemiology, Biostatistics, and Clinical Research [Paris], Centre d'Investigation Clinique – Épidémiologie Clinique [Paris], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Gamal Abdel Nasser de Conakry, Centre Antituberculeux de la Carrière [Conakry, Guinée], Laboratoire National des Mycobactéries [Conakry, Guinée], Urgences Réanimation [Paris], Centre Hospitalier Sud Essonnes (CHSE), Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université Paris Cité (UPCité), Bodescot, Myriam, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Institut de Recherche pour le Développement (IRD)-Université de Paris (UP) |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male medicine.medical_specialty Tuberculosis 030231 tropical medicine HIV Infections lcsh:Infectious and parasitic diseases Body Mass Index Medication Adherence Cohort Studies Young Adult 03 medical and health sciences BMI 0302 clinical medicine Interquartile range Latent mixed models [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Internal medicine Tuberculosis Multidrug-Resistant Culture conversion Humans Medicine lcsh:RC109-216 Multidrug-resistant 030212 general & internal medicine Antibiotics Antitubercular Depression (differential diagnoses) Retrospective Studies 2. Zero hunger Depression business.industry Weight change Retrospective cohort study Middle Aged medicine.disease 3. Good health Regimen Dyspnea Infectious Diseases [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Female [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Rifampin business Body mass index Research Article |
Zdroj: | BMC Infectious Diseases BMC Infectious Diseases, 2020, 20 (1), pp.315. ⟨10.1186/s12879-020-05028-0⟩ BMC Infectious Diseases, BioMed Central, 2020, 20 (1), pp.315. ⟨10.1186/s12879-020-05028-0⟩ BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020) |
ISSN: | 1471-2334 |
DOI: | 10.1186/s12879-020-05028-0⟩ |
Popis: | Background Despite the predictive role of body weight variation in treatment outcome in multidrug-resistant tuberculosis (MDR-TB), few corroborating data are available. We studied weight variation in patients with MDR-TB to identify groups of weight change and to determine factors that influence these changes. Methods We analyzed patients with rifampicin resistance who were treated with an MDR-TB treatment regimen between June 07, 2016 and June 22, 2018 at three major drug-resistant TB centers in Guinea. Patients were seen monthly until the end of treatment. Clinical outcome was the body mass index (BMI). We used a linear mixed model to analyze trajectories of BMI and a latent class mixed model to identify groups of BMI trajectories. Results Of 232 patients treated for MDR-TB during the study period, 165 were analyzed. These patients had a total of 1387 visits, with a median of 5 visits (interquartile range, 3–8 visits). Monthly BMI increase was 0.24 (SE 0.02) per kg/m2. Factors associated with faster BMI progression were success of MDR-TB treatment (0.24 [SE 0.09] per kg/m2; p = 0.0205) and absence of lung cavities on X-ray (0.18 [0.06] per kg/m2; p = 0.0068). Two groups of BMI change were identified: rapid BMI increase (n = 121; 85%) and slow BMI increase (n = 22; 15%). Patients in the slow BMI increase group were mostly female (68%) had no history of TB treatment (41%), had a positive HIV infection (59%), and had a more severe clinical condition at baseline, characterized by a higher frequency of symptoms including depression (18%), dyspnea (68%), poor adherence to MDR-TB treatment (64%), lower platelet count, and higher SGOT. These patients also had a longer time to initial culture conversion (log-rank test: p = 0.0218). Conclusion Quantitative BMI data on patients with MDR-TB treated with a short regimen allowed the identification of subgroups of patients with different trajectories of BMI and emphasized the usefulness of BMI as a biomarker for the monitoring of MDR-TB treatment outcome. |
Databáze: | OpenAIRE |
Externí odkaz: |